denosumab – Xgeva

On the Horizon – Denosumab (Xgeva) to Slow the Development of Bone Mets

Amgen has submitted a supplemental Biologics License Application (sBLA) to the FDA to expand the indication for denosumab (XGEVA) its RANK ligand inhibitor to treat men with castrate-resistant prostate cancer to reduce the risk of developing bone metastases. If approved, denosumab would be the first therapy licensed to prevent or delay the spread of cancer [...]

By Malecare|2011-07-13T12:16:49-04:00July 13th, 2011|Advanced Prostate Cancer, denosumab - Xgeva, Drugs & Treatments, FDA, On The Horizon, Uncategorized, Understanding APC|0 Comments

On The Horizon – Xgeva (denosumab) To Prevent or Slow Down Bone Mets

Yesterday, Amgen announced that it had submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) to expand its license for XGEVA® (denosumab) to treat men with castrate-resistant prostate cancer to reduce the risk of developing bone metastases. If approved, XGEVA would be the first therapy licensed to prevent or [...]

By Malecare|2011-06-27T23:08:22-04:00June 27th, 2011|Advanced Prostate Cancer, bisphosphonates, Clinical Trials, Clinical Trials, denosumab - Prolia, denosumab - Xgeva, Drugs & Treatments, FDA, Metastases, On The Horizon, Uncategorized, Understanding APC|0 Comments

Previous 23